EQRx, Inc. – the startup that was created to bring radically lower-priced medicines to market – has changed its strategy to bring two Chinese-developed drugs to the US market based on shifts in FDA regulatory requirements. The company updated investors on plans to get the two drugs licensed in the US during its second quarter sales and earnings call on 11 August.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?